Tomer Kariv is Director at Eloxx Pharmaceuticals, Inc. (ELOX). They have made 8 open-market trades across 5 companies since 2016, most recently 2025-06-04.
CIK 0001568077
8 open-market purchases totalling $40.9M since 2016, never a sale. Across 7 scored buys the stock is up 13.3% at ninety days, and 7.4 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 86% | 71% | 57% |
| Avg Move | +9.5% | +14.1% | +13.3% |
| Alpha | +3.1% | +12.2% | +7.4% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ELOX | BUY | 2021-05-13 | 2021-05-17 | $1.35 | $16.0M | +3.5% | +45.8% | -15.3% |
| KROS | BUY | 2020-04-13 | 2020-04-13 | $16.00 | $7.0M | +24.5% | +21.4% | +30.1% |
| ELOX | BUY | 2019-06-24 | 2019-06-26 | $9.00 | $1.8M | +1.4% | -13.7% | -42.5% |
| VBIV | BUY | 2018-12-17 | 2018-12-18 | $1.40 | $4.0M | +11.9% | +34.3% | +38.5% |
| LOGC | BUY | 2018-10-23 | 2018-10-25 | $10.00 | $4.2M | -13.8% | -11.9% | -11.9% |
| ELOX | BUY | 2018-04-30 | 2018-05-01 | $9.75 | $6.8M | +9.5% | +10.6% | +12.3% |
| ELOX | BUY | 2018-03-21 | 2018-03-23 | $7.76 | $98K | +29.6% | +12.1% | +81.7% |
| ARNI | BUY | 2016-01-12 | 2016-01-14 | $0.35 | $1.0M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.